Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Tripadvisor Inc Common Stock — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Tripadvisor Inc Common Stock trades at $13.89 (market cap $1.63B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 24.5× Tripadvisor Inc Common Stock's market cap, and Tripadvisor Inc Common Stock is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | TRIP | |
|---|---|---|
Market Cap | $39.89B | $1.63B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $19.14 |
52-Week Low | $278.09 | $9.24 |
Enterprise Value | $38.15B | $1.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
TRIP trades at $13.98, up 4.88% today, near the consensus price target of $13.87. The stock shows a bullish technical signal with support at $13 and resistance at $14. Recent earnings have been mixed, with a beat in Q3 2025 but misses in Q4 2025 and Q1 2026. The company's $700 million sale of TheFork to American Express in June 2026 provides a cash infusion but highlights strategic refocusing amid competitive pressures.
The outlook is cautious; while the sale simplifies the business and boosts liquidity, core revenue growth remains modest and net margins are thin at 0.99%. Analyst sentiment is neutral with 60.72% hold ratings. Key risks include execution on the narrowed strategy and travel industry volatility. The stock appears fairly valued with a P/E of 127.09 reflecting low earnings, but the P/S of 0.93 suggests potential if top-line expansion accelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
